ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.32 0.37 (2.32%) Market Cap: 2.71 Bil Enterprise Value: 2.20 Bil PE Ratio: 90.67 PB Ratio: 5.23 GF Score: 74/100

ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 07:00PM GMT
Release Date Price: $53.57 (-1.56%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon or good morning from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov, I'm the senior large-cap biotech analyst, and it's my pleasure to introduce our next company ACADIA Pharmaceuticals and CEO, Steve Davis. Please note that following this presentation, we will have a Q&A session where you have the ability to submit questions via the little blue button in your conference portal.

So with that, Steve, thanks for being here today, and let me turn things over to you.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Great. Thanks much, Cory. Hello, everyone, and thank you for joining us today. I'm Steve Davis, CEO of Acadia Pharmaceuticals. Just a brief reminder that the business of pharmaceutical development and commercialization has certain inherent risks. So please refer to Slide 2 of this presentation and a copy of our most recent SEC filings for a description of those risks as they relate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot